Javascript must be enabled to continue!
HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta‐analysis and trend analysis
View through CrossRef
AbstractAimsIn Iran, injecting drug use has been the major route of human immunodeficiency virus (HIV) transmission. In order to control the HIV epidemic, a harm reduction program was initiated and has been expanded in recent years. The aim of this study was to provide an updated estimate of HIV prevalence among people who inject drugs (PWID) in Iran, investigate prevalence differences over time and assess prevalence correlates.DesignA comprehensive systematic review was undertaken in the international, regional and national bibliographic databases in November 2018 and extensive contacts with authors were made. For studies conducted before 2005, we used data from a previous published systematic review.SettingAll studies conducted in Iran were included. Recruitment settings included anywhere except studies conducted in infectious diseases wards or HIV counseling centers.ParticipantsPWID with any definition utilized in the studies. Thirty‐six studies were included, which were conducted in 24 of 31 provinces with a sample size of 22 160 PWID.MeasurementsWe included studies that had performed HIV testing and had a confirmed diagnosis of HIV through repeating the enzyme‐linked immunosorbent assay (ELISA) or Western immunoblot assay (WB). Pooled prevalence of HIV was calculated for the total sample and for different subgroups, by available socio‐demographic and behavioral factors. For assessing the trend of HIV prevalence over time, a linear meta‐regression model was fitted separately for before 2007 and during 2007 and afterwards.FindingsThe pooled prevalences of HIV before 2007 and in 2007 and afterwards were 14.3% [95% confidence interval (CI) = 9.8–18.9] and 9.7% (95% CI = 7.6–11.9), respectively. HIV prevalence increased until 2005–06 and then slowly declined until 2009–10, which was not significant. Prevalence of HIV was significantly higher in PWID above age 25 years, and in those with history of imprisonment and history of needle/syringe‐sharing. HIV prevalence was higher in men than in women, but the difference was insignificant.ConclusionThe prevalence of HIV among people who inject drugs in Iran decreased after 2006 which could, at least in part, be attributed to the development of extensive harm reduction programs in the country.
Title: HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta‐analysis and trend analysis
Description:
AbstractAimsIn Iran, injecting drug use has been the major route of human immunodeficiency virus (HIV) transmission.
In order to control the HIV epidemic, a harm reduction program was initiated and has been expanded in recent years.
The aim of this study was to provide an updated estimate of HIV prevalence among people who inject drugs (PWID) in Iran, investigate prevalence differences over time and assess prevalence correlates.
DesignA comprehensive systematic review was undertaken in the international, regional and national bibliographic databases in November 2018 and extensive contacts with authors were made.
For studies conducted before 2005, we used data from a previous published systematic review.
SettingAll studies conducted in Iran were included.
Recruitment settings included anywhere except studies conducted in infectious diseases wards or HIV counseling centers.
ParticipantsPWID with any definition utilized in the studies.
Thirty‐six studies were included, which were conducted in 24 of 31 provinces with a sample size of 22 160 PWID.
MeasurementsWe included studies that had performed HIV testing and had a confirmed diagnosis of HIV through repeating the enzyme‐linked immunosorbent assay (ELISA) or Western immunoblot assay (WB).
Pooled prevalence of HIV was calculated for the total sample and for different subgroups, by available socio‐demographic and behavioral factors.
For assessing the trend of HIV prevalence over time, a linear meta‐regression model was fitted separately for before 2007 and during 2007 and afterwards.
FindingsThe pooled prevalences of HIV before 2007 and in 2007 and afterwards were 14.
3% [95% confidence interval (CI) = 9.
8–18.
9] and 9.
7% (95% CI = 7.
6–11.
9), respectively.
HIV prevalence increased until 2005–06 and then slowly declined until 2009–10, which was not significant.
Prevalence of HIV was significantly higher in PWID above age 25 years, and in those with history of imprisonment and history of needle/syringe‐sharing.
HIV prevalence was higher in men than in women, but the difference was insignificant.
ConclusionThe prevalence of HIV among people who inject drugs in Iran decreased after 2006 which could, at least in part, be attributed to the development of extensive harm reduction programs in the country.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
686. Comparing Treatments of Methicillin-Resistant Staphylococcus aureus Infective Endocarditis by People Who Inject Drugs
686. Comparing Treatments of Methicillin-Resistant Staphylococcus aureus Infective Endocarditis by People Who Inject Drugs
Abstract
Background
People who inject drugs (PWID) are at high risk for infective endocarditis (IE) with high-mortality pathogen...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study
Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study
Abstract
Background
In Rwanda, epidemiological data characterizing people who inject drugs (PWID) and their burden of HIV...
Prevalence of HIV in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis
Prevalence of HIV in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis
The Eastern Mediterranean Region (EMR) has historically been considered a low-HIV-prevalence region. However, emerging evidence suggests a rapidly evolving epidemic, with the EMR n...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Prevalence and willingness to access HIV services among people who inject drugs in the northern states of Nigeria
Prevalence and willingness to access HIV services among people who inject drugs in the northern states of Nigeria
Abstract
Background:
People who inject drugs (PWID) face a dual risk of contracting human immunodeficiency virus (HIV) through needle sharing and...
Inequitable Access of People Who Injected Drugs to HCV Care in Tangier, Morocco: An Explorative Qualitative Study
Inequitable Access of People Who Injected Drugs to HCV Care in Tangier, Morocco: An Explorative Qualitative Study
Abstract
BackgroundWorldwide, approximately 16 million people inject drugs, 5 to 6 million people are living with hepatitis C virus (HCV) infection. In Morocco, people who ...

